Recently we demonstrated that closed chromatin composed of Polycomb proteins and histone 3 lysine 27 trimethylation impedes CRISPR-mediated genome editing by blocking the accessibility of chromosomal DNA to spCas9/sgRNA. Editing efficiencies were higher in cells where the same reporter locus had not been repressed, thus we presume that silenced chromatin can be modified to generate a Cas9-accessible state. To test this idea, we exposed the locus to antagonists of Polycomb silencing: Gal4-p65, a targeted transcriptional activator, and UNC1999, a chemical inhibitor of the histone H3K27 methyltransferase EZH2. For both we observed loss of histone trimethylation. Only Gal4-p65 treatment increased target gene expression. Initial Gal4-p65 overexpression impedes Cas9 activity, while a 9-day recovery period leads to enhanced Cas9 efficiency up to 1000 bp from the Gal4 binding site. No enhancement was observed with UNC1999.
INTRODUCTION
CRISPR/Cas9, a nucleic acid modifying system derived from prokaryotes, is a popular tool for rapid, high-throughput genome engineering in eukaryotic nuclei. 1, 2 Mounting evidence suggests that chromatin, the RNA-DNA-protein complex that mediates eukaryotic chromosomal organization and gene expression, [3] [4] [5] inhibits Cas9 binding and nuclease activity in vitro [6] [7] [8] and at many genomic sites in metazoan cells. 9, 10 While many Cas9 gene editing efforts have been successful, the complex structure of chromatin and its variation in different cells still pose a barrier to reliable and consistent use. [8] [9] [10] [11] A growing body of work has determined the strong influence of chromatin on the accessibility of DNA to Cas9, guide RNA complexes (Cas9/gRNA), and Cas9 editing efficiency. [8] [9] [10] [11] A series of in vitro studies using reconstituted nucleosomes formed from synthetic DNA and histones have demonstrated that Cas9-mediated binding and cleaving of nucleosomal DNA is completely blocked. [6] [7] [8] Although these results might have limited relevance for chromosomal DNA since synthetic sequences used in these studies associate more tightly with histones, 12, 13 studies in mammalian cells corroborate the observation that chromatin structure can impede CRISPR activity.
Surveys of CRISPR efficiencies at chromosomal sites in HEK293T, HeLa, human fibroblast 14 , and mouse embryonic stem cells 15 have shown that heterochromatin (closed chromatin) is less accessible to CRISPR editing than euchromatin (open chromatin). Utilizing transgenic cell lines, we and others have shown that ectopic HP1-mediated 9 and Polycomb Repressive Complex (PRC)-mediated 10 heterochromatin decrease, and in some cases completely block, Cas9 binding and editing in HEK293 cells. Interestingly, editing at three out of nine sites within a PRC-repressed region was not blocked, suggesting that inhibition of Cas9 can be discontinuous across regions of closed chromatin. 10 In vivo , dynamic chromatin organization poses a barrier to reliable CRISPR-mediated editing as demonstrated in zebrafish. 16 Research so far suggests that remodeling or disruption of closed chromatin might generate a more Cas9-permissive state. For instance, a recent study showed that deactivated Cas9 (dCas9)
can be used as an an artificial pioneer factor to increase DNase hypersensitivity, which indicates depletion or relocation of bound proteins (i.e., histones), at several loci in mouse embryonic stem cells 17 . In another study, dCas9 was used to increase accessibility of a nearby target site to an active Cas9 nuclease 18 . This effect was was observed at sites within 50 bp of the dCas9 target. For CRISPR applications where unique pioneer factor target sites are not available at this proximity, more distal remodeling activity may be desired. To achieve greater control over Cas9-mediated editing in heterochromatin, further investigation is needed to determine the relationship between CRISPR activity and the impact of dynamic features found across broader regions, including transcriptional elongation, histone modifications, and association of non-histone proteins (Fig. 1 ). Polycomb proteins support histone compaction and block access of DNA to RNA polymerase and Cas9.
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Chromatin remodelers (not shown), histone acetyltransferases (HATs), and histone methyltransferases (HMTs), generate modifications that support open chromatin, accessible DNA, and a transcriptionally permissive state. 19, 20 To this end, we investigated how perturbations of the closed chromatin state impact Cas9-mediated editing by attempting to re-open chromatin that was previously closed by Polycomb-complex (PRC) formation at an ectopic site. Polycomb group (PcG) protein-driven gene silencing is conserved across metazoans, from simple echinoderms to plants and large land vertebrates 21 . PRC-mediated silencing (Fig. 1A) is elevated in stem cells 22, 23 and cancer cells [24] [25] [26] [27] at loci that are central to cell development and are therefore likely targets of interest for gene editing. Polycomb-regulated targets are distributed over thousands of sites along chromosome arms in gene-rich regions. Therefore, PRC's present a significant barrier to genome engineering efforts. In our previous work, we tested a variety of artificially-induced expression states at a PRC-repressed reporter gene and found that siRNA-mediated knockdown of the PcG protein Suz12 ( Fig. 1 ) was accompanied by partial recovery of Cas9-mediated editing efficiency at a single CRISPR target site. 10 Here, we expanded our investigation to determine transcriptional states and histone modifications that are associated with CRISPR-accessibility over a broader region of DNA (1000 bp). Experiments with transcription-activating proteins in cells 28 and with nucleosome arrays in vitro 7, 8 suggest that expression-associated chromatin remodeling could improve Cas9 efficiency in human cells. To test this idea we measured two signatures of the conversion from epigenetic silencing to activation, gene expression and activation-associated histone modifications, at a PRC-repressed site that was subjected to transcription factor targeting or specific inhibition of H3K27 methylation. We determined the associated changes in CRISPR editing efficiency using a sensitive deep sequencing assay. We found that strong induction of transcription by the p65 subunit of NF-kB followed by culturing for several days resulted in sustained gene expression and the restoration of full Cas9 activity at a target site approximately 1000 bp downstream of the promoter. Specific inhibition of the histone K27 methyltransferase EZH2, and concomitant depletion of H3K27me3, was not sufficient to enhance gene expression nor Cas9 editing efficiency.
Our results suggest that reorganization of chromatin after transcriptional elongation supports accessibility of DNA to Cas9 activity over a broad region of chromatin.
MATERIALS AND METHODS

Cell Lines and Plasmids
Development of the Luc14 and Gal4-EED/luc HEK293 cell lines is described in Hansen et al.
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Cas9/gRNA-expressing cells were generated via transfection of pU6-(BbsI)_CBh-Cas9-T2A-EGFP (DNASU UnSC00746685), which was built from pX330-U6-Chimeric_BB-CBh-hSpCas9 (a gift from Feng Zhang, Addgene plasmid #42230) as previously described 30 .
pU6-(BbsI)_CBh-Cas9-T2A-EGFP generates a single mRNA transcript that encodes the human optimized spCas9 protein and EGFP, separated by a T2A translation-skipping signal. Guide RNAs sg025, sg032, sg046, and sg048 were cloned into pU6-(BbsI)_CBh-Cas9-T2A-EGFP as previously described 30 . Gal4-p65 (a Gal4-mCherry-p65 fusion protein) was expressed from plasmid CMV-Gal4p65_MV1 (DNASU UnSC00746686). Annotated sequences for the plasmids used in this study are available online at https://benchling.com/hayneslab/f_/V1mVw1Lp-chromatin-crispr-interference/.
Cell Culturing and Transfection
Cell culturing, luciferase silencing, and transfections of the Luc14 and GAL4-EED HEK293 cell lines were performed as previously described 30 . Gal4-EED/luc cells were treated with doxycycline (dox) for 96 h to induce silencing, then cells were grown in fresh dox-free medium (DMEM, 10%
fetal bovine serum, 5% penicillin-streptomycin) for 24 h. For Gal4-p65 overexpression, ~2.0E5 cells per well were transfected in 12-well plates with Lipid-DNA complexes (500 ng plasmid, 3 μl Lipofectamine LTX, 1 μl Plus Reagent (Life Technologies)). Cells were collected for analyses 72 h post transfection for all but the Gal4-p65 pre-treatment assays. For EZH2 inhibition, cells were treated with 1 μl 10 μM UNC1999 (Cayman Chemical) at a final dilution of 1.0E-3 μM in i ml growth medium for 72 h. Control cells were treated with 1 μl of DMSO (vehicle) per 1 ml media. Cells were grown in fresh UNC1999-free, DMSO-free medium for 24 h prior to Luciferase assays (described below) or ChIP-qPCR (Supporting Information).
Luciferase Assays
Transfection efficiencies for Gal4-p65-expressing cells were determined by measuring the percent of live, mCherry-positive cells using the BD Accuri C6 Flow Cytometer and accompanying software (BD Biosciences) as previously described 30 . Luciferase signal from 100 μl of cells was normalized by the number of live cells, which was determined by flow cytometry (using side-and forward-scatter gating) of 20 μl from each sample. Luciferase assays were performed in triplicate per experimental or control sample with a Synergy H1 Multi-Mode Reader (Biotek) using the Steady-Luc Firefly HTS Assay Kit (Biotium) 30 . Luciferase activity per cell was calculated as follows:
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Deep Sequencing to Determine Cas9 Editing Efficiency
Cells were collected after 72 h of growth following transfection with pU6-(BbsI)_CBh-Cas9-T2A-EGFP (DNASU UnSC00746685) with sgRNA sg025, sg032, sg046, or sg048. 10 Transfection efficiency was determined using flow cytometry to measure EGFP signal as previously described. 30 Genomic DNA was extracted from the remaining 200 μl of cells using the QIAamp DNA Mini Kit (Qiagen) and eluted in 100 μl of nuclease-free water. PCR of gDNA was performed using GoTaq 2x Mastermix (Promega) using primers P198/198 (see Table S2 for sequences) [95℃ for 10 min; 34x (95℃, 30 sec; 58℃, 30 sec; 72℃, 20 sec.)]. Nested PCR was performed by diluting 2 μl of PCR product into 500 μl of water and Phusion High-Fidelity DNA Polymerase (Thermo Scientific), using the primers described in Table S1 and S2. DNA was purified from PCR reactions using the Genelute PCR Cleanup Kit (Sigma-Aldrich) and submitted to the Center for Computational and Integrative Biology (CCIB) Core Facility (Massachusetts General Hospital) according to their requirements for sequencing.
Quantitative PCR of ChIP DNA
Chromatin Immunoprecipitation is described in Supporting Information. Relative quantification of
ChIP samples was performed using real-time quantitative PCR and SYBR Green I master mix (Roche) as previously described. 10 To adjust for input dilution, log2 (20) 
Statistical Analyses
The percentage of edited reads was normalized to transfection efficiency for each sample. 
RESULTS
The fusion activator Gal4-p65 alters the transcriptional state and histone modifications at
PRC-repressed chromatin
Our previous work demonstrated that a fusion transcriptional activator composed of the Gal4 DNA binding domain and the p65 protein (from NF-kB) can activate gene expression at a PcG-silenced luciferase gene. 10 P65 is known to interact with several transcriptional activators that potentially counteract PcG-mediated siencing, including histone acetyltransferases (CREBBP and EP300), and H3K4 methyltransferases (EHMT1 and SETD7) (STRING database 31 ). We asked whether p65
targeting near the promoter and its presumed recruitment of endogenous factors could induce sustained transcriptional activation and chromatin remodeling at the PcG-silenced luciferase transgene.
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We used Gal4-EED/luc cells as a model system for PRC-mediated closed chromatin. Upon treatment with doxycycline (dox), the cells express a Gal4-embryonic ectoderm development (EED) fusion protein which binds to a Gal4 enhancer sequence (UAS) upstream of the thymidine kinase ( Tk ) core promoter of a luciferase transgene. EED recruits PcG proteins (Fig. 1) , resulting in accumulation of the H3K27me3 silencing mark, the PRC1 complex, and luciferase silencing. (Fig. S1 ). This result, together with previous studies of the dynamics of the system, suggest that UAS-Tk-luciferase not significantly influenced by surrounding endogenous chromatin.
We measured the change in luciferase expression, the silencing-associated H3K27me3 mark, and the activation-associated H3K4me3 mark in cells expressing the Gal4-p65 activator. We detected strong and sustained re-activation of luciferase at 3 days and 9 days following transfection with Gal4-p65-expressing plasmids ( Fig. 2A) . We also detected a significant reduction in the amount of H3K27me3 ( p < 0.05) (Fig. 2B) . To determine whether p65 targeting results in addition of active chromatin modifications, we measured enrichment of H3K4me3. We observed less H3K4me3 in the silenced state compared to Luc14 ( p = 0.06) (Fig. 2B ) and a significant increase of H3K4me3 in the reopened state versus the silenced state ( p < 0.01).
Interestingly, our data reveal that PRC-repressed luciferase is both H3K27me3-positive and H3K4me3-positive (Fig. 2B) . A previous study of the Gal4-EED/luc cell line 29 showed that PRC accumulation leads to a reduction in, but not a complete disappearance of H3K4me3 at luciferase .
This result is consistent with the appearance of "bivalent" chromatin at poised, inactive genes 32 and
suggests that silenced UAS-Tk-luciferase may be a useful model to study the impact of bivalent chromatin on CRISPR activity. Still, H3K4me3 levels were significantly higher after Gal4-p65-induced luciferase activation, suggesting that a greater proportion of H3K4me3 to
H3K27me3 is associated active expression. 
Chromatin de-silencing by Gal4-p65 restores CRISPR activity at a distal site
Gal4-p65-induced activation of luciferase and the accompanying changes in chromatin structure (Fig. 2B ) led us to hypothesize that local chromatin remodeling via Gal4-p65 would enhance Cas9-mediated editing at a site that was previously blocked by closed chromatin. In our 2017 study, we tested this idea by co-transfecting luciferase -silenced HEK293 cells with a Gal4-p65-expressing and Cas9/gRNA-expressing plasmids. 10 Luciferase became activated, suggesting a transcriptionally permissive state, but editing efficiency was not significantly higher at the target site we tested, sg034. Also in the previous study, we observed a decrease in editing efficiency at sg034 in the open chromatin state that was hyper-activated by Gal4-p65 suggesting competition between Gal4-p65 and Cas9/gRNA might contribute to reduction in Cas9 activity.
In the current study, we carried out the same treatment (co-expression of Gal4-p65 with CRISPR plasmids) at sites located in the same 1.1 kb region as sg034: sg046, 32, 25, and 48 ( Fig.   2B , Table S2 ). Sg046, 32, and 48 were chosen to represent sites where Cas9 activity is inhibited by closed chromatin. 10 These sites also represent varying distances from the activator binding site: sg046 and 32 are proximal to the Gal4 UAS sequence (within 300 bp) while sg048 is distal (>1000 bp downstream of the TSS). Sg025 shows no change in editing efficiency within closed chromatin 10 and was therefore used here as a control for uninhibited CRISPR activity. At 72 hours post-transfection, we collected the treated cells and assayed for Cas9 editing using deep sequencing to quantify the proportions of insertion and deletion (INDEL) variants generated by non-homologous end-joining (NHEJ) repair. We detected editing efficiencies at or below closed chromatin levels for sg032, 25, and 48 or sg046, respectively, (Fig. 2B, Closed +Gal4-p65) . 10 The most frequent INDELs showed no obvious change in position relative the predicted cut sites (Fig.   2C ), suggesting no change in Cas9 specificity or NHEJ products.
To reconcile the opposing effects of Gal4-p65 targeting, i.e. induction of an active chromatin state versus inhibition of Cas9's access to DNA, we asked whether transient Gal4-p65 expression followed by a recovery period to allow for depletion of Gal4-p65 (referred to here as "pre-treatment") would generate a Cas9-accessible state. Having established that transcription and activation-associated histone modifications were sustained 9 days after initial overexpression of Gal4-p65 (Fig. 2) , we set out to determine CRISPR activity at luciferase after Gal4-p65 pre-treatment, compared to co-treatment with Gal4-p65 and CRISPR (Fig. 3A) . For pre-treatment, we transfected the Gal4-p65 plasmid alone and then one of the four Cas9/gRNA plasmids 9 days later (2 cell passages). As with co-treatment, we did not observe significant differences in editing efficiency at the control site sg025. At one proximal site (sg032) and the distal site (sg048), the mean editing efficiency approached full recovery (open chromatin levels). The most significant enhancement of editing was observed at the distal site sg048 ( p < 0.005, Closed +Gal4-p65, 9 day recovery versus closed chromatin). The target site closest to the heterochromatin nucleation site and the TSS, sg046, showed no significant increase in editing compared to the closed chromatin control sample. Overall, these results suggest that initial, transient overexpression results in Gal4-p65 accumulation and activator recruitment that inhibits Cas9 activity by blocking access of Cas9/gRNA to the target sites. This is followed by gradual remodeling of chromatin into a state that enhances Cas9-mediated editing at sites downstream of the TSS. 
Depletion of H3K27me3 via EZH2 inhibition is not sufficient to generate an active expression state
Next, we investigated the contribution of H3K27me3 demethylation to de-silencing of PRC-repressed luciferase and restoration of CRISPR-mediated editing. UNC1999 is a small molecule drug that binds to the active site of the methyltransferase Enhancer of zeste 2 (EZH2) to halt the methylation at H3K27me3, a modification that supports PRC formation and a closed chromatin state. 33 UNC1999 is a potent inhibitor that has been used for complete depletion of H3K27me3 in MCF7 and HEK293 cells. 33 We induced repressive chromatin at luciferase with dox-supplemented media for 96 hours. At 120 hours, we cultured the cells in a sub-lethal dose of UNC1999 (1.0E-3 μM) for 120 hours. At 264 hours, we measured Luciferase activity and performed chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to determine H3K27me3 enrichment.
While UNC1999 did not significantly increase Luciferase activity (Fig. 4A ), we saw a significant decrease in H3K27me3 compared to the DMSO control ( p < 0.01) (Fig. 4B) . We conclude that at 1.0E-3 μM, UNC1999 depletes H3K27me3 from the silenced transgene but does not stimulate transcriptional activation under the conditions tested here. This finding is consistent with previous work where removal of the H3K27me3 silencing mark alone did not activate gene expression in embryonic stem cells, 34 and DNA methylation and gene silencing persisted after depletion of EZH2 in cancer cells. 35 The effect of UNC1999 allowed us to investigate the impact of H3K27 modification on CRISPR activity independently of the elevated expression that was observed with transcriptional activation via Gal4-p65. Depletion of H3K27me3 by inhibition of EZH2 is not sufficient to restore CRISPR activity in
PRC-repressed chromatin
Next, we investigated whether removal of H3K27me3 via inhibition of EZH2 (Fig. 5A ) was sufficient to improve Cas9 editing. We measured Cas9 activity in cells that were subjected to the same DMSO and UNC1999 treatments we used for the expression and ChIP-qPCR assays. At 24 hours after DMSO or UNC1999 removal, we transfected cells with plasmids expressing Cas9/sgRNA that targetes site sg046, 32, 25, or 48 at luciferase (Fig. 5B) . At 72 hours post-transfection, we collected the treated cells and assayed for Cas9 editing using deep sequencing. UNC1999 treatment did not restore Cas9 editing at any of the four target sites tested. Furthermore, at two target sites, treatment with UNC1999 showed an even greater inhibition than in the vehicle control (sg046 p < 0.001 and sg025 p < 0.01). Since inhibition of endogenous EZH2 has a global effect on genomic chromatin, it is difficult to interpret this result. The position of the most frequently edited sites (the nucleotide immediately adjacent the predicted cut site) was the same under all conditions (Fig. 5C ),
suggesting that treatment with UNC1999 did not alter the pattern of editing. We conclude that UNC1999 treatment under these conditions does not improve Cas9-mediated editing at sites in PRC-repressed chromatin. 
DISCUSSION
We determined the impact of de-silenced and H3K27me3-depleted Polycomb-enriched chromatin within a 1000 bp chromosomal region in a human cell line. We targeted spCas9 to four sites along a luciferase transgene within ectopic PRC-associated chromatin. Three sites showed inhibition by heterochromatin (sg046, 32, and 48) while one site (sg025) was unaffected. We confirmed our observation from previous work that strong transcriptional activation driven by Gal4-p65 initially inhibits Cas9 activity. 10 A recovery period of 9 days following Gal4-p65 expression (pre-treatment) lead to sustained activation of luciferase, loss of H3K27me3, an increase in H3K4me3, and enhancement of Cas9/gRNA activity at two sites. The most significant enhancement was observed for a site ~1000 bp downstream of the activator target site.
While UNC1999 effectively removed H3K27me3 from the luciferase transgene (Fig. 4B) , it
was not sufficient to induce gene activation (Fig. 4A ) or enhance Cas9 editing at the sites tested ( Fig. 5B and C) . This is consistent with previous observations where removal of H3K27me3 did not result in gene activation 34 or remodeling of chromatin to an open state; gene silencing and other repressive modifications can persist after the loss of PcG proteins. 35 siRNA-mediated knockdown of the non-enzymatic PRC protein Suz12 showed modest enhancement of CRISPR activity in our previous study 30 , as well as a small increase in luciferase expression. Along with the results from our Gal4-p65 experiments, these observations suggest a role for gene expression or expression-associated chromatin modifications in generating the Cas9/gRNA-accessible state.
Expression-associated chromatin modifications may work in concert with or independently of
H3K27me3 depletion to open repressed chromatin. Specific inhibitors of epigenetic enzymes other than the compound investigated here warrant further investigation. These could be used to interrogate the role of other chromatin features, including DNA methylation and histone deacetylation, in modulating access of DNA by CRISPR.
We demonstrated that targeted remodeling using a strong activator (p65) enhances Cas9-mediated editing roughly 1000 bp downstream from the Gal4 binding site (UAS) of a model transgene, luciferase . Targeted hyper-activation can generate a Cas9-accessible state in the ectopic chromatin model system used here, under specific conditions. We confirmed our previous observation that high-transcriptional activity can impede Cas9 editing possibly through steric 14 hindrance and competition with the high occupancy of the UAS site with activator proteins and RNA PolII. Co-treatment with the Gal4-p65 activator showed no improvement in editing and, at one site, significant inhibition compared to the silenced state ( Fig. 3B and C) . In contrast, pre-treatment with the activator enhanced Cas9 editing near open-chromatin levels at target sites previously inhibited by closed chromatin (Fig. 3B and C) . Pre-treatment also led to depletion of the H3K27me3 silencing mark, accumulation of H3K4me3 activating marks, and gene activation (Fig. 2) . This suggests that chromatin remodelers recruited by Gal4-p65, i.e. histone acetyltransferases (CREBBP and EP300), and H3K4 methyltransferases (EHMT1 and SETD7), or transcriptional elongation remove or displace nucleosomes or the silencing marks.
To make these findings more broadly applicable for CRISPR enhancement, the Gal4 having a neutral effect on gene expression 17, 18 . Our study is a significant step towards manipulating chromatin across broader regions to enhance the efficacy of CRISPR-mediated genome editing.
